- Home
- PDSB vs CLYM Comparison
PDSB vs CLYM Comparison
Compare PDSB & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDSB
- CLYM
- Stock Information
- Founded
- PDSB 2005
- CLYM 2018
- Country
- PDSB United States
- CLYM United States
- Employees
- PDSB N/A
- CLYM N/A
- Industry
- PDSB Biotechnology: Pharmaceutical Preparations
- CLYM
- Sector
- PDSB Health Care
- CLYM
- Exchange
- PDSB Nasdaq
- CLYM NYSE
- Market Cap
- PDSB 72.2M
- CLYM 83.8M
- IPO Year
- PDSB N/A
- CLYM 2021
- Fundamental
- Price
- PDSB $1.24
- CLYM $1.37
- Analyst Decision
- PDSB Strong Buy
- CLYM Buy
- Analyst Count
- PDSB 2
- CLYM 1
- Target Price
- PDSB $10.00
- CLYM $10.00
- AVG Volume (30 Days)
- PDSB 473.1K
- CLYM 389.6K
- Earning Date
- PDSB 08-12-2025
- CLYM 08-13-2025
- Dividend Yield
- PDSB N/A
- CLYM N/A
- EPS Growth
- PDSB N/A
- CLYM N/A
- EPS
- PDSB N/A
- CLYM N/A
- Revenue
- PDSB N/A
- CLYM N/A
- Revenue This Year
- PDSB N/A
- CLYM N/A
- Revenue Next Year
- PDSB N/A
- CLYM N/A
- P/E Ratio
- PDSB N/A
- CLYM N/A
- Revenue Growth
- PDSB N/A
- CLYM N/A
- 52 Week Low
- PDSB $0.85
- CLYM $1.05
- 52 Week High
- PDSB $4.42
- CLYM $9.21
- Technical
- Relative Strength Index (RSI)
- PDSB 39.29
- CLYM N/A
- Support Level
- PDSB $1.20
- CLYM N/A
- Resistance Level
- PDSB $1.40
- CLYM N/A
- Average True Range (ATR)
- PDSB 0.10
- CLYM 0.00
- MACD
- PDSB -0.03
- CLYM 0.00
- Stochastic Oscillator
- PDSB 12.50
- CLYM 0.00
About PDSB PDS Biotechnology Corporation
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.